The Oncotrition GmbH is a privately owned biotechnology company, which was founded in Leipzig, Germany in 2012 as a spin off from the Fraunhofer Institute for Cell Therapy and Immunology (IZI). Oncotrition dedicates itself to scientific experimentation to support the development of innovative nutritional therapeutics for the treatment of cancer-associated cachexia and also the prevention of standard cancer treatment associated side effects.


The company’s primary focus is the development of nutritional strategies to prevent cancer cachexia, which should begin immediately after the diagnosis of cancer. The company is currently completing the development stage for the first product line and is now proceeding to the production stage, verifying the efficacy.